Received Dec 12, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
she started to experience fever and body aches; she started to experience fever and body aches; This non-serious case was reported by a consumer via call center representative and described the occurrence of fever in a female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (1st dose received on an unknown date). On 03-DEC-2025, the patient received the 2nd dose of Shingrix. On 03-DEC-2025, less than a day after receiving Shingrix, the patient experienced fever (Verbatim: she started to experience fever and body aches) and general body pain (Verbatim: she started to experience fever and body aches). Rechallenge with Shingrix was positive. The outcome of the fever and general body pain were not resolved. It was unknown if the reporter considered the fever and general body pain to be related to Shingrix. It was unknown if the company considered the fever and general body pain to be related to Shingrix. Linked case(s) involving the same patient: US2025AMR157774 Additional Information: GSK Receipt Date: 04-DEC-2025 The batch number was not provided, and we are unable to contact the reporter.; Sender's Comments: US-GSK-US2025AMR157774: